Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. - Wikidata - wikimedia - TriplyDB

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

http://www.wikidata.org/entity/Q36393927

about

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis Understanding heart failure with preserved ejection fraction: where are we today?Breakthrough in heart failure with preserved ejection fraction: are we there yet?Clinical adoption of prognostic biomarkers: the case for heart failure Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem Understanding the epidemic of heart failure: past, present, and future Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies Patient selection in heart failure with preserved ejection fraction clinical trials Heart failure with preserved ejection fraction Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Heart failure with preserved ejection fraction.Early Detection of Heart Failure Using Electronic Health Records: Practical Implications for Time Before Diagnosis, Data Diversity, Data Quantity, and Data Density.Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.Developing therapies for heart failure with preserved ejection fraction: current state and future directions Update on heart failure with preserved ejection fraction.Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology Comorbidity profiles and inpatient outcomes during hospitalization for heart failure: an analysis of the U.S. Nationwide inpatient sample.Multi-state modelling of heart failure care path: A population-based investigation from Italy Phenotypic spectrum of heart failure with preserved ejection fraction.Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium Exercise physiology in heart failure and preserved ejection fraction.Rethinking Phase II Clinical Trial Design in Heart Failure.Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction Association of comorbidity burden with abnormal cardiac mechanics: findings from the HyperGEN study Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance Examination of the potential association of stress with morbidity and mortality outcomes in patient with heart failure.Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles.Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial.Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients.Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.Care of older adults Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction.

P2860

Q21132299-B6675E79-F0F7-44F8-A9FA-BC01BE42A350 Q26766590-DD3AEEDF-18A8-4EAC-8231-DC046085B096 Q26771999-7605E4F6-1D60-4051-9106-21F96C504942 Q26863716-22AAA084-E924-42C2-8A70-1C4A9FCB74B9 Q26991985-5C44E3DC-D6DF-40FC-8406-5FDA92686F1C Q26996486-DDF535CE-EF6C-4B22-8899-C64BC1035C2B Q27000263-6D9703D8-E784-47CE-986B-F7677C6D7ADC Q27015845-D6821986-FECA-42A2-9DF6-6B99BC686E1E Q27024008-3713EE3A-A4B2-4465-B9D8-73CE7892C162 Q28073079-0C9E36F4-9277-4083-A45E-BE79DDFED403 Q28088503-DA760A4C-404F-4F71-8109-44BCC72ABCB5 Q30250020-B6E7EEB7-3718-4EBD-A323-6D353D300E0F Q30420528-E69DD8F8-C63B-425D-96E6-E74C0A7AF8F1 Q31171239-9510DA79-715C-4B2F-8F34-C8A98BF3F506 Q33164540-21E070C7-8030-450D-B264-381569628E72 Q33639223-49EAD3A7-8359-4AFC-85E0-3ECC767AC9DC Q33640339-09AF8A32-EE51-4197-AF1F-F02A3953CFC7 Q33748856-CF7CA5A8-CC37-459F-9995-E95132224E7D Q33756448-11A6E8B8-5F14-4F91-ABCF-D11F38D89D10 Q33773244-0EDACA82-4BF4-4415-84F4-BD50C44B7EEF Q33827302-DE21EEF8-22ED-4113-BB4C-F9F0E8B91FB6 Q33889242-2309E7F1-1045-4BD5-B8E0-F1870A926672 Q34053617-58119C68-67D5-4EDC-8CA0-9CFAFE76DE24 Q34377514-AE34C259-2101-4AF8-84BC-86C002150065 Q34625223-52D8E192-061F-4F57-A287-DF29A52F5620 Q35021761-F6B499DD-E39B-4F9F-B4BA-C0BC4F1302AA Q35139959-1ECF9650-C255-49A8-96C0-8D57523EF787 Q35725839-C9DDD647-C2CE-42E1-942B-5BD55639FDF0 Q35911866-528D7A7C-81C3-4B78-9A40-148D21BA188C Q35913203-853E2EEE-0357-4988-AAA5-918C255659BC Q36072399-91A15256-64E8-462F-96FA-BBC16267BD68 Q36097850-5B1468E1-9E00-4C02-9017-71FA9542359E Q36141629-D1785563-FA47-4A71-847B-FCFEB3FE07C6 Q36199988-E1390F36-7C0E-40BE-A549-E4FD241E7F4E Q36203267-5BCE8167-AD3B-4EB6-9174-2BBBFBF823D6 Q36290215-0B07FF18-6F1E-4601-A54D-AA37CAB23EF6 Q36303452-068B6D5C-AF22-44E0-8785-8014C3E71665 Q36578409-63E6500C-F6EC-4773-9704-A5079B2A7794 Q36623186-040DFDA5-4AE0-4B26-83BB-1FBFB06BE04B Q36683918-C8BB88EB-0A38-41DA-A15D-C5A05400B452

P2860

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

http://www.wikidata.org/entity/Q36393927

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Impact of noncardiac comorbidi ...... sus reduced ejection fraction.

@ast

Impact of noncardiac comorbidi ...... sus reduced ejection fraction.

@en

type

label

Impact of noncardiac comorbidi ...... sus reduced ejection fraction.

@ast

Impact of noncardiac comorbidi ...... sus reduced ejection fraction.

@en

prefLabel

Impact of noncardiac comorbidi ...... sus reduced ejection fraction.

@ast

Impact of noncardiac comorbidi ...... sus reduced ejection fraction.

@en

P1433

Q36393927-8716DC34-694E-49D1-B07A-D607CEDA0AE6

P1476

Q36393927-211D765C-CC87-4645-BB22-9DAF2AF86369

P2093

Q36393927-101DB038-A8C6-418E-9AC9-6E04EC74C52B

Q36393927-2A5F4FBA-C92D-430F-978E-E4C9D1B137C5

Q36393927-599B3699-3F67-4C87-BA95-1B40F43CC991

Q36393927-72D5FBB9-EECA-423A-92BC-EDE9A0DA38E5

Q36393927-A2728ACE-2CC2-40A7-BA2C-1A4E0FC43CFB

Q36393927-D1EA3DCD-C121-4E98-B59C-79E0C86FA9F9

P2860

Q36393927-008D404C-D59E-42A3-8C7E-3DE53E63C5E7

Q36393927-09AED5E5-E41D-4F61-804D-BEA93F407B89

Q36393927-157C8521-F231-47BD-89E1-2DECF3945933

Q36393927-39766B81-F450-41EB-BE2A-726421D20C4C

Q36393927-42024DD3-4EDD-4236-9815-1341901CA8F7

Q36393927-5C2022D5-4876-4806-B051-88A5996BF020

Q36393927-67F271E0-B6D4-4E17-9A1F-180BB780DB7E

Q36393927-6F2AD7D9-67FB-4991-8B18-6E1F72225619

Q36393927-823A93B6-52D3-4FC0-AD91-3778414A9D96

Q36393927-94836D22-AC50-4626-8EA8-005940508C2B

P304

Q36393927-71AC76BF-D0B1-4575-B97E-335D989BE4C4

P31

Q36393927-FE260292-D558-4D55-84E2-68B0600D5966

P356

Q36393927-B7242503-29C8-4BEE-80E4-EA902A5C3B34

P407

Q36393927-BE018D10-7D21-47DA-93B8-04C02454515D

P433

Q36393927-DD0B8DE9-7C53-4DEF-8826-0FDDDD8A8C41

P478

Q36393927-EA380CF7-F4BA-4DD0-BB1F-4A34BA792663

P50

Q36393927-413FD4DA-C1AB-406F-BE08-767FBB0DF357

Q36393927-CE19E730-8688-4BE5-ADB2-93C24280443E

P577

Q36393927-733FE34E-4BEE-462E-A397-0650DB4DDCCD

P5875

Q36393927-0D698938-E5C2-4EA0-ADEF-5DCA457CAD72

P698

Q36393927-9455E096-4DE6-408B-9380-4A7C76EBE9DF

P921

Q36393927-B9494640-AC15-434C-A20F-8A37553F2674

P932

Q36393927-6120B863-22CA-4C9E-9DFB-016880CC203C

P356

J.JACC.2011.11.040

P1433

Journal of the American College of Cardiology

P1476

Impact of noncardiac comorbidi ...... rsus reduced ejection fraction

@en

P2093

Amit A Zachariah

http://www.w3.org/2001/XMLSchema#string

Anita Deswal

http://www.w3.org/2001/XMLSchema#string

Biykem Bozkurt

http://www.w3.org/2001/XMLSchema#string

David Aguilar

http://www.w3.org/2001/XMLSchema#string

Kumudha Ramasubbu

http://www.w3.org/2001/XMLSchema#string

Wenyaw Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Outcome of heart failure with preserved ejection fraction in a population-based study

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction.

Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology

Hospitalizations after heart failure diagnosis a community perspective.

Heart failure with preserved systolic function. A different natural history?

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Treatment of hypertension in patients 80 years of age or older.

P304

998-1005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2011.11.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Xander H T Wehrens

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221688064

http://www.w3.org/2001/XMLSchema#string

P698

22402071

http://www.w3.org/2001/XMLSchema#string

P921

P932

4687406

http://www.w3.org/2001/XMLSchema#string